Geographic data shows that while production is global, the Human Insulin Market region of North America continues to lead in total revenue. This dominance is due to high healthcare expenditure and the early adoption of advanced analogs. However, Europe is quickly becoming a hub for biosimilar innovation, with several key approvals paving the way for lower-cost alternatives to high-priced...